[Ip-health] KEI comments at HHS listening session on WHA72 concerning the transparency resolution

Claire Cassedy claire.cassedy at keionline.org
Tue May 7 07:45:33 PDT 2019


https://www.keionline.org/30666

KEI comments at HHS listening session on WHA72 concerning the transparency
resolution

Posted on May 7, 2019 by James Love

On Agenda item 11.7 – Access to medicines and vaccines[1], KEI offers the
following comments on the transparency resolution.

1. Transparency should not be controversial. Policy makers and the public
need to have better evidence in order to support policies that shape
access, affordability and innovation.

2. KEI is among the many groups that have long advocated for greater
transparency in markets for biomedical inventions. Our web page on
transparency in markets for biomedical inventions is here:
https://keionline.org/transparency. Among the items linked on the page is a
memo[2] prepared by KEI for the WHA negotiations on transparency, that
cites numerous expert reports, resolutions, regulations and directives on
transparency, a page[3] that provides links to dozens of U.S. legislative
proposals on transparency, and many other items.

3. HHS, the USPTO and other federal agencies have engaged constructively in
the negotiations over the draft resolution on transparency. The most recent
text of the proposed resolution (https://www.keionline.org/30617) reflects
several changes that address concerns raised earlier by the United States.

4. There is a public goods aspect of several of the proposed disclosures.
R&D disclosures have a global benefit. The national disclosures of prices
will be more challenging for some countries, as the debate in the US
illustrates. Having a longer term goal for pricing transparency is useful,
even if it takes a while to get there.

5. The current draft of the transparency resolution has focused on the
areas of R&D transparency that are the most manageable. Clinical trial
outlays can be directly associated with specific products and services, and
the risks can be reasonably evaluated.

6. Pre-clinical R&D transparency is now designated to be addressed later,
beginning with a report on challenges and opportunities for transparency on
this topic by the WHO R&D observatory.

7. The proposed web-based tool for governments to share information is
clearly voluntary, but if helpful, the text can be explicit that the
sharing is voluntary.

8. Some countries will not be able to link disclosures and reports in the
resolution to registration of product of services without changes in
national statutes or European Union regulations. To address this issue, the
obligation to make disclosures can be tied to coverage or reimbursements,
areas where some governments have more flexibility in requiring information
from sellers of products and services.


[1] http://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_1-en.pdf
[2]
https://docs.google.com/document/d/1QMPxxdwVxeR94qOKq-ihZe2BCe8YtGgz9mtlscuh0Vk/edit?usp=sharing
[3] https://www.keionline.org/transparency-bills-UScongress


More information about the Ip-health mailing list